Pay in 4 interest-free payments of $6.10 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Who Profits: Eli Lilly (LLY) FY2025 Revenue: $63.5B | GLP-1 Revenue (Mounjaro + Zepbound): $35-38B (estimated) | Operating Margin: 31% | CEO (David Ricks): $24.3M This issue's mechanism: Eli Lilly is winning the market share battle against Novo
Given that peptides send messages to cells with instructions regarding what those cells should become theyre pretty important when it comes to the functioning of our body
- As I grapple for concrete ways to shift health discourses away from total self-dominion toward communal, de-commodified care, Im reminded of a Mental Hellth essay from 2022 (that I was stunned to realize is also by James Greig.) The essay concerns the cultural shift toward blaming depression and anxiety on superstructures rather than individual things like unlucky brain chemistry or lackluster self-care habits
Yes MT-2 activates the melanocortin-4 receptor pharmacologically, but when the peptide is removed, receptor signaling returns to baseline and appetite increases accordingly
If reactions persist despite addressing these factors, you may have sensitivity to GHK-Cu itself
US$ 24.32
US$ 21.73
US$ 24.04
